vs
Side-by-side financial comparison of Arena Group Holdings, Inc. (AREN) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
Arena Group Holdings, Inc. is the larger business by last-quarter revenue ($28.2M vs $18.7M, roughly 1.5× CytomX Therapeutics, Inc.). Arena Group Holdings, Inc. runs the higher net margin — 18.9% vs -0.8%, a 19.7% gap on every dollar of revenue. On growth, Arena Group Holdings, Inc. posted the faster year-over-year revenue change (-22.0% vs -25.7%). Over the past eight quarters, Arena Group Holdings, Inc.'s revenue compounded faster (-1.2% CAGR vs -15.9%).
Arena Racing Company, also called ARC Racing and Leisure Group is a UK private company, created in 2012 by the merger of Arena Leisure and Northern Racing. It owns and operates 16 racecourses in Great Britain, accounting for 39% of British racing fixtures. It also operates hotels at Wolverhampton Racecourse, Lingfield Park Racecourse and Doncaster Racecourse and golf courses at Lingfield, Southwell and Newcastle.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
AREN vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.2M | $18.7M |
| Net Profit | $5.3M | $-154.0K |
| Gross Margin | 43.6% | — |
| Operating Margin | 26.6% | -6.9% |
| Net Margin | 18.9% | -0.8% |
| Revenue YoY | -22.0% | -25.7% |
| Net Profit YoY | -22.5% | 97.6% |
| EPS (diluted) | $0.12 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.2M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $45.0M | $18.7M | ||
| Q1 25 | $31.8M | $50.9M | ||
| Q4 24 | $36.2M | $38.1M | ||
| Q3 24 | $33.6M | $33.4M | ||
| Q2 24 | $27.2M | $25.1M | ||
| Q1 24 | $28.9M | $41.5M |
| Q4 25 | $5.3M | — | ||
| Q3 25 | $6.9M | — | ||
| Q2 25 | $108.6M | $-154.0K | ||
| Q1 25 | $4.0M | $23.5M | ||
| Q4 24 | $6.9M | $18.9M | ||
| Q3 24 | $4.0M | $5.7M | ||
| Q2 24 | $-8.2M | $-6.5M | ||
| Q1 24 | $-103.4M | $13.8M |
| Q4 25 | 43.6% | — | ||
| Q3 25 | 50.2% | — | ||
| Q2 25 | 56.5% | — | ||
| Q1 25 | 49.3% | — | ||
| Q4 24 | 52.6% | — | ||
| Q3 24 | 50.6% | — | ||
| Q2 24 | 39.4% | — | ||
| Q1 24 | 30.9% | — |
| Q4 25 | 26.6% | — | ||
| Q3 25 | 31.9% | — | ||
| Q2 25 | 36.5% | -6.9% | ||
| Q1 25 | 23.1% | 44.4% | ||
| Q4 24 | 28.6% | 46.4% | ||
| Q3 24 | 24.0% | 12.3% | ||
| Q2 24 | -9.5% | -33.7% | ||
| Q1 24 | -27.5% | 28.1% |
| Q4 25 | 18.9% | — | ||
| Q3 25 | 23.1% | — | ||
| Q2 25 | 241.4% | -0.8% | ||
| Q1 25 | 12.6% | 46.2% | ||
| Q4 24 | 19.0% | 49.6% | ||
| Q3 24 | 11.8% | 17.2% | ||
| Q2 24 | -30.1% | -26.0% | ||
| Q1 24 | -357.1% | 33.3% |
| Q4 25 | $0.12 | — | ||
| Q3 25 | $0.14 | — | ||
| Q2 25 | $2.28 | — | ||
| Q1 25 | $0.08 | — | ||
| Q4 24 | $1.23 | — | ||
| Q3 24 | $0.11 | — | ||
| Q2 24 | $-0.28 | — | ||
| Q1 24 | $-3.91 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.3M | $49.0M |
| Total DebtLower is stronger | $97.6M | — |
| Stockholders' EquityBook value | $-4.8M | $119.9M |
| Total Assets | $112.6M | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.3M | — | ||
| Q3 25 | $12.5M | — | ||
| Q2 25 | $6.8M | $49.0M | ||
| Q1 25 | $2.9M | $47.6M | ||
| Q4 24 | $4.4M | $38.1M | ||
| Q3 24 | $5.8M | $40.6M | ||
| Q2 24 | $6.1M | $43.2M | ||
| Q1 24 | $4.0M | $36.2M |
| Q4 25 | $97.6M | — | ||
| Q3 25 | $110.5M | — | ||
| Q2 25 | $110.5M | — | ||
| Q1 25 | $110.5M | — | ||
| Q4 24 | $110.4M | — | ||
| Q3 24 | $102.4M | — | ||
| Q2 24 | $102.4M | — | ||
| Q1 24 | $102.3M | — |
| Q4 25 | $-4.8M | — | ||
| Q3 25 | $-10.4M | — | ||
| Q2 25 | $-17.3M | $119.9M | ||
| Q1 25 | $-126.1M | $25.0M | ||
| Q4 24 | $-130.3M | $-456.0K | ||
| Q3 24 | $-137.5M | $-23.5M | ||
| Q2 24 | $-157.2M | $-31.2M | ||
| Q1 24 | $-149.6M | $-31.7M |
| Q4 25 | $112.6M | — | ||
| Q3 25 | $121.4M | — | ||
| Q2 25 | $127.8M | $175.1M | ||
| Q1 25 | $114.6M | $98.5M | ||
| Q4 24 | $116.4M | $120.5M | ||
| Q3 24 | $114.2M | $139.0M | ||
| Q2 24 | $113.4M | $159.2M | ||
| Q1 24 | $120.3M | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.1M | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | 2.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.1M | — | ||
| Q3 25 | $12.2M | — | ||
| Q2 25 | $10.3M | $-15.8M | ||
| Q1 25 | $3.7M | $-21.0M | ||
| Q4 24 | $-8.6M | $-19.9M | ||
| Q3 24 | $-2.3M | $-20.7M | ||
| Q2 24 | $-3.2M | $-19.5M | ||
| Q1 24 | $-2.0M | $-26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | $-2.4M | $-20.7M | ||
| Q2 24 | — | $-19.6M | ||
| Q1 24 | — | $-26.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | -7.1% | -62.1% | ||
| Q2 24 | — | -78.2% | ||
| Q1 24 | — | -63.1% |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | 2.46× | — | ||
| Q3 25 | 1.77× | — | ||
| Q2 25 | 0.09× | — | ||
| Q1 25 | 0.91× | -0.89× | ||
| Q4 24 | -1.25× | -1.05× | ||
| Q3 24 | -0.59× | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AREN
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
